These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 16230088

  • 1. Does celecoxib use increase the risk of cardiovascular events?
    Oviedo JA, Schroy PC.
    Gastroenterology; 2005 Oct; 129(4):1348-50. PubMed ID: 16230088
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.
    White WB, West CR, Borer JS, Gorelick PB, Lavange L, Pan SX, Weiner E, Verburg KM.
    Am J Cardiol; 2007 Jan 01; 99(1):91-8. PubMed ID: 17196469
    [Abstract] [Full Text] [Related]

  • 5. Cyclooxygenase-2 inhibitors and cardiovascular risk.
    Smith ER.
    Can J Cardiol; 2005 Mar 01; 21(3):307-8. PubMed ID: 15776124
    [No Abstract] [Full Text] [Related]

  • 6. Does the pro-hypertensive effect of cyclooxygenase-2 inhibitors account for the increased risk in cardiovascular disease?
    Messerli FH, Sichrovsky T.
    Am J Cardiol; 2005 Sep 15; 96(6):872-3. PubMed ID: 16169380
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease.
    Ray WA, MacDonald TM, Solomon DH, Graham DJ, Avorn J.
    Pharmacoepidemiol Drug Saf; 2003 Sep 15; 12(1):67-70. PubMed ID: 12616850
    [No Abstract] [Full Text] [Related]

  • 9. Coxibs and cardiovascular risk.
    Allen MJ, McLean-Veysey P, Fleming I.
    CMAJ; 2005 Oct 11; 173(8):853. PubMed ID: 16217098
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: what does evidence from randomised trials show about celecoxib?
    Underhill JL.
    BMJ; 2005 Dec 17; 331(7530):1474-5. PubMed ID: 16356996
    [No Abstract] [Full Text] [Related]

  • 16. [Selective Cox-2 inhibitor in osteoarthritis and rheumatoid arthritis. No increased risk for the heart].
    MMW Fortschr Med; 2003 Mar 13; 145(11):60. PubMed ID: 12688204
    [No Abstract] [Full Text] [Related]

  • 17. Risks and benefits of celecoxib to prevent recurrent adenomas.
    Psaty BM, Potter JD.
    N Engl J Med; 2006 Aug 31; 355(9):950-2. PubMed ID: 16943408
    [No Abstract] [Full Text] [Related]

  • 18. Coxib toxicity: a likely class effect.
    Prescrire Int; 2005 Feb 31; 14(75):22. PubMed ID: 15751177
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF, Hsiao FY, Wen YW, Tsai YW.
    Clin Ther; 2006 Nov 31; 28(11):1827-36. PubMed ID: 17213003
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.